The Societal Cost of Alzheimer's Disease depends on the Diagnosis Timing
Gagliardi, G. P.; Bonnet, N.; Schoentgen, B.; Defontaines, B.
Show abstract
BackgroundAlzheimers disease (AD) is a major public health issue with rising prevalence due to global aging. In France, official estimates report a societal cost of {euro}2.3 billion, however likely underestimating the true economic burden. MethodsA comprehensive economic model was developed to estimate the ADs societal cost in France. The model incorporated diagnosis timings (early, average, late), disease stages (MCI, mild, severe AD), direct and indirect costs, and different payors. ResultsTotal annual costs ranged from {euro}32.5B (late diagnosis) to {euro}36.5B (early). Early diagnosis increased total costs but reduced indirect burdens on patients. Key cost included medical expenses and home-based medical-social support. Per-patient costs varied between {euro}62,000 (early MCI) and {euro}175,000 (late sAD). ConclusionEarlier diagnosis increases total expenditures but improves care and cost allocation. Current and future medications focusing on the early stages of the disease, we need to invest in early diagnosis, which will reduce future expenditure.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Variation in real world dementia risk profiles in 6171 adults drawn from the Australian CogDrisk website according to demographic characteristics 91%
- COVID19-related and all-cause mortality among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection in the region of Tarragona, Spain: results from the COVID19 TARRACO Cohort Study, March-June 2020 90%
- Impact of non-pharmaceutical interventions on COVID-19 incidence and deaths: cross-national natural experiment in 32 European countries 89%
Similar papers in this journal
- Socioeconomic inequalities and diabetes complications: An analysis of administrative data from Hungary 90%
- A regression discontinuity analysis of the social distancing recommendations for older adults in Sweden during COVID-19 89%
- Comparison of Healthcare costs and benefits of the UK’s Covid-19 response with four European countries: Decision Modelling Study 89%
Similar papers in this journal
- Developing a core outcome set for interventions in people with mild cognitive impairment: study protocol 90%
- Association of social isolation, loneliness, and genetic risk with incidence of dementia: UK Biobank cohort study 90%
- Development and validation of an algorithm to estimate the risk of severe complications of COVID-19 to prioritise vaccination 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.